FTC launches healthcare task force with weight loss and telehealth marketing in its sights

Federal Trade Commission Chairman Andrew N. Ferguson issued a memorandum on March 20, 2026 directing the agency to create an internal Healthcare Task Force ^[1]. The memo names misleading telehealth and weight loss programs among the consumer protection matters the agency has acted on and intends to keep pursuing ^[1].

According to the memo, the task force is meant to break down silos inside the FTC and between it and other agencies, so that enforcement and policy work across healthcare are aligned ^[1]. The FTC describes healthcare as roughly 18% of U.S. GDP and points to a gap between that spending and patients' continued difficulty getting affordable care ^[1]. The memo ties those problems to consolidation and other allegedly anticompetitive conduct in healthcare markets, and to regulations that it says may weaken incentives to cut costs or improve quality ^[1]. It calls out particular effects on rural communities, seniors and veterans ^[1].

What the memo puts on notice

On the consumer protection side, the memo lists "misleading telehealth and weight-loss programs" among healthcare actions the agency has brought, along with deceptive health plan marketing and products promoted with unsupported claims for serious conditions ^[1]. The memo says any entity marketing health-related products or services should expect continued enforcement around claims substantiation, disclosures, endorsements and steering ^[1]. In plain terms, that covers whether advertisers can back up what they claim, what they tell customers up front, how they use endorsements, and how they direct consumers toward particular products or services.

The task force is also set to run ongoing "horizon-scanning" to spot emerging issues, which the memo says is likely to include digital health, telehealth, artificial intelligence-enabled tools and health data platforms ^[1]. The FTC's Office of Technology is expected to play a meaningful role ^[1]. Participation is to be expanded to other government entities, including the Department of Health and Human Services and the Department of Justice, along with other agency and law enforcement partners ^[1].

On competition, the memo keeps consolidation in focus, covering transactions involving hospitals, physician groups, payors, pharmacy benefit managers (PBMs), device manufacturers and other healthcare players, especially those affecting innovation or vulnerable patient populations ^[1]. It also highlights PBM practices, prescription drug pricing and transparency, and says PBMs, plan sponsors and manufacturers should expect continued attention to rebates, formulary design, steering and related practices ^[1].

The task force is to draw on the Bureau of Competition, the Bureau of Consumer Protection, the Bureau of Economics, the Office of Policy Planning and the Office of Technology ^[1]. It does not have authority to issue new statutes or regulations, but it formalizes an integrated investigative and enforcement structure that the agency hopes will let it move more quickly on matters that cross antitrust, consumer protection and technology ^[1].

Why it matters for patients

People shopping for weight loss treatment online often see ads, telehealth sign-up pages and testimonials that make strong promises. The memo signals that the FTC is organizing itself to look at those kinds of promotions more closely, specifically flagging claims substantiation, disclosures, endorsements and steering as areas of continued enforcement ^[1]. That matters for anyone comparing brand-name GLP-1 drugs with compounded versions or with telehealth weight loss programs sold through ads, because the standards applied to the advertising are the same regardless of which product is being pitched ^[1].

The memo does not name any drug, company or compounded product, and it does not describe new rules that would change what is legally sold or prescribed ^[1]. It also does not change insurance coverage, pricing or prescribing rules, which are handled elsewhere ^[1].

What happens next

The directive to create the task force is dated March 20, 2026 ^[1]. No date for the task force's first meeting, no list of specific targets, and no enforcement actions tied to the task force have been reported ^[1]. Whether compounded semaglutide or tirzepatide marketing becomes a specific focus has not been disclosed.